504P Prognostic factors of patients with AFP-positive colorectal cancer: A case-control study

Abstract

Methods: We retrospectively analyzed the mutational landscape (excluding Variants of Unknown Significance) in 64 consecutive patients with synchronous mCRC who underwent a comprehensive genomic profiling with the Guardant360 74 gene panel at baseline and at first tumor progression according to UPTR in the context of tumour location and RAS status. The Variant Allele Fraction (VAF%) and the total number of new alterations at first progression were evaluated.Results: 1-The total number of new alterations at first progression was higher in all subgroups for the non UPTR patients (Table ):The median number of metastatic sites at baseline was the same between both subgroups although more irresectable metastatic sites were found in the non UPTR subgroup 2-For Left side + rectum locations either wild-type or mutant, the median VAF% was higher at baseline and at first progression in patients without UPTR as compared with UPTR. This was not the case in the right-side mutant subgroup: Left

A Case Report on Alpha-Fetoprotein-Positive Colorectal Cancer

“…Theories have suggested that AFP-producing tumors tend to originate from the foregut, unlike colorectal tissues, which originate from the hindgut endoderm [ 3 ]. A case-control study showed that the AFP-producing CRC has worse disease-free survival (DFS) at 23.3 months versus 26.0 months in AFP-negative CRC patients ( P = 0.003) [ 4 ]. Here, we report a case of a patient with primary AFP-producing CRC, which was successfully treated with surgery and adjuvant chemotherapy.…”